Agemica founder Ronjon Nag on the moonshot company he believes will develop a vaccine for aging and make a dramatic difference to lifespan and healthspan.
Agemica is on a mission to create a vaccine for aging; its platform uses an AI-driven approach to seek out antiaging therapies that address root causes of aging and leverage those to prevent diseases of aging such as neurodegeneration, cardiovascular disease, immune system failure and cancer.
The company hopes its omics-based tech will extend both lifespan and healthspan, and the platform has already been validated in 17 cancer areas and predicted antiaging candidates that have higher efficacy, reduced side effects and lower chances of developing drug resistance.
Agemica's aim is to extend the number of indications of its candidates and pave the way, not only to better patient outcomes, but to therapies that hit the market much faster. We sat down with CEO and Cofounder Dr Ronjon Nag to find out how the platform works, its revolutionary potential and the diseases of aging Agemica has in its sights.
Visit Agemica here: agemica.com/
------------------------------
Visit Longevity.Technology - bit.ly/3PwtH8Y
Follow Longevity.Technology on:
Twitter - bit.ly/3AMIXuq
Facebook - bit.ly/3z8H1v5
Instagram - bit.ly/3IDvVRX
LinkedIn - bit.ly/3yIfDmf
15 янв 2024
